ソラフェニブ投与中にｋｅｒａｔｏａｃａｎｔｈｏｍａを合併した肝細胞癌の一例

DOI Web Site Web Site 被引用文献1件 参考文献9件

書誌事項

タイトル別名
  • Keratoacanthoma in a patient receiving sorafenib for the treatment of hepatocellular carcinoma
  • ソラフェニブ トウヨ チュウ ニ keratoacanthoma オ ガッペイ シタ キモ サイボウガン ノ イチレイ

この論文をさがす

抄録

Sorafenib is a newly approved multikinase inhibitor for the treatment of unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma. Sorafenib is associated with a relatively high incidence of cutaneous adverse events. We report the first case of 88-year-old man with HCC who developed keratoacanthoma (KA) during sorafenib therapy in Japan. He presented with a hyperkeratotic papule on right forearm 6 months after starting sorafenib. Excisional biopsy confirmed the clinical diagnosis of KA. Recently, in the English literatures, KA and squamous cell carcinoma (SCC) have been reported to occur in 6-7% of the patients treated with sorafenib, but, in Japan, the development of KA or SCC has not been described in association with sorafenib. Careful dermatologic monitoring of these patients to ensure early detection of KA or SCC is recommended.<br>

収録刊行物

  • 肝臓

    肝臓 52 (12), 787-789, 2011

    一般社団法人　日本肝臓学会

被引用文献 (1)*注記

もっと見る

参考文献 (9)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ